Results 71 to 80 of about 14,363 (238)

ZeroPM piece 12 PBPK modelling

ZeroPM Pieces, 2022
ZeroPM piece 12 about PBPK modelling. The presentation can be viewed as a film on the ZeroPM youtube channel.
openaire   +1 more source

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Translocation of gold nanoparticles across the lung epithelial tissue barrier: Combining in vitro and in silico methods to substitute in vivo experiments [PDF]

, 2015
The lung epithelial tissue barrier represents the main portal for entry of inhaled nanoparticles (NPs) into the systemic circulation. Thus great efforts are currently being made to determine adverse health effects associated with inhalation of NPs ...
Bachler, Gerald, Goetz, Natalie von, Hungerbuehler, Konrad, Losert, Sabrina, Petri-Fink, Alke, Rodriguez-Lorenzo, Laura, Rothen-Rutishauser, Barbara, Umehara, Yuki   +7 more
core   +1 more source

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Building Pharmacoequity through Student and Trainee Education, Service, and Global Outreach

Clinical Pharmacology &Therapeutics, EarlyView.
Students and trainees are integral to clinical pharmacology, as they have the potential to shape the field. This perspective highlights how the ASCPT Student and Trainee Community engages members worldwide, providing opportunities and resources to advance scientific and professional development.
Chazmyn Riley, Natasha Desiree Casas, Patricia D. Maglalang, Hongyu Su, An Le, Shravani Etrouth, Shayna R. Killam, MaryPeace McRae   +7 more
wiley   +1 more source

A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug–Drug–Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine

Pharmaceutics, 2020
Physiologically-based pharmacokinetic (PBPK) modeling is a well-recognized method for quantitatively predicting the effect of intrinsic/extrinsic factors on drug exposure.
Tobias Kanacher, Andreas Lindauer, Enrica Mezzalana, Ingrid Michon, Celine Veau, Jose David Gómez Mantilla, Valerie Nock, Angèle Fleury   +7 more
doaj   +1 more source

A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development [PDF]

, 2012
Peer ...
Becker, T, Brosch, M, Görlitz, L, Hampe, J, Kuepfer, L, Laffert, B, Lippert, J, Meyer, M, Neuvonen, PJ, Niemi, M, Schafmayer, C, Schreiber, S, Siegmund, H.-U, von Kampen, O   +13 more
core   +1 more source

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2015
The US Food and Drug Administration (FDA) public workshop, entitled “Application of Physiologically‐based Pharmacokinetic (PBPK) Modeling to Support Dose Selection focused on the role of PBPK in drug development and regulation. Representatives from industry, academia, and regulatory agencies discussed the issues within plenary and panel discussions ...
Wagner, C, Zhao, P, Pan, Y, Hsu, V, Grillo, J, Huang, SM, Sinha, V   +6 more
openaire   +2 more sources

PKRxiv: A Best Practice Model for Advancing Pharmacoequity Through Open Pharmacokinetic Data Sharing

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development is increasingly integrated across the drug development continuum, enabling more efficient, cost‐effective, and targeted trials while reducing reliance on animal studies. Achieving pharmacoequity requires not only equitable access to medicines but also to the data and knowledge that inform drug development and regulatory ...
Shakir Atoyebi, Prajith Venkatasubramanian, Abdulafeez Akinloye, Oluwasegun Eniayewu, Brookie M. Best, Laura Else, Adeniyi Olagunju   +6 more
wiley   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, EarlyView.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source